The class
A review describes proof-of-principle preclinical and clinical results for a semi-annual CETP vaccine to raise HDL and address unmet cardiovascular need (Vascul Pharmacol 2006)
Original title: Vaccines for the prevention of cardiovascular disease
While highly effective LDL-lowering therapies have gained widespread adoption, therapeutic options for raising low HDL, a key independent coronary heart disease risk factor, remain limited. This review describes a vaccine approach to raising HDL cholesterol by inducing an immune response against endogenous cholesteryl ester transfer protein (CETP), for which proof of principle has been demonstrated in preclinical and clinical models. The authors propose this vaccine approach could address low HDL cholesterol with a cost-effective semi-annual injection, offering an alternative to conventional small-molecule CETP inhibitors.
Original abstract
Atherosclerosis, especially coronary heart disease (CHD), remains a most significant global public health problem. Highly effective LDL-lowering therapies have gained widespread adoption in the United States and throughout the developed world, but therapeutic options for raising low HDL, a key independent risk factor for CHD, remain limited. We are developing a vaccine approach to raising HDL, by inducing an immune response to endogenous cholesteryl ester transfer protein (CETP), and have demonstrated proof of principle in preclinical and clinical models. This vaccine approach may offer the opportunity to address low HDL with a cost-effective semi-annual injection.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.